Total Lymphocyte Count, Neutrophil-Lymphocyte Ratio, and Platelet-Lymphocyte Ratio as Prognostic Factors in Advanced Non-Small Cell Lung Cancer with Chemoradiotherapy [Corrigenudm]

This article refers to:

Total lymphocyte count, neutrophil–lymphocyte ratio, and platelet–lymphocyte ratio as prognostic factors in advanced non–small cell lung cancer with chemoradiotherapy

Song X, Chen D, Yuan M, Wang H, Wang Z. Cancer Manag. 2018;10:6677–6683

On page 6677, Abstract, Results subheading, the median baseline PLR should be 136.1.

On page 6680, Results section, 2^nd paragraph, the median baseline PLR should be 136.1.

On page 6680, the red curve should be PLR ≥136.1 and the blue cure should be PLR <136.1. The COX analysis was not correct in the previous publication and it has been revised and shown below in the new Tables 1 and table 2. The correct Figure 3 is shown below.

Figure 3 Kaplan–Meier plots of overall survival among patients who receivedchemoradiotherapy for advanced NSCLC stratified by baseline PLR.

Abbreviations: NSCLC, non–small cell lung cancer; PLR, platelet-to-lymphocyteratio.

Table 2 Univariate analysis of factors potentially associated with overall survival

Characteristics	HR	95% CI	P Value
Age ≥65	0.778	0.609–0.994	0.045
Male	0.935	0.733–1.193	0.588
KPS score ≥70	1.100	0.762-1.588	0.611
TNM stage IIIB	1.024	0.763-1.375	0.874
Current smoker	0.918	0.748-1.126	0.412
Receipt of induction chemotherapy	1.127	0.881-1.443	0.342
Receipt of concurrent chemotherapy	0.868	0.660-1.143	0.314
Pretreatment TLC ≥2.4 × 10^3/μL	0.594	0.464-0.759	<0.001
Pretreatment NLR ≥3.4	2.280	1.776–2.927	<0.001
Pretreatment PLR ≥136.1	1.745	1.364-2.232	<0.001

Abbreviations: HR, hazard ratio; CI, confidence interval; ECOG PS, Eastern Cooperative Oncology Group performance status; TNM, tumor-nodes-metastasis; TLC, total lymphocyte count; NLR, neutrophil-to-lymphocyte ratio; PLR, platelet-to-lymphocyte ratio.

On page 6680, Table 2, the COX analysis was not correct in the previous publication and it has been revised. The correct Table 2 is shown below.

On page 6681, Table 3, the COX analysis was not correct in the previous publication and it has been revised. The correct Table 3 is shown below.

Table 3 Multivariate analysis of factors potentially associated with overall survival Model 1 (TLC included)

	Model 1 (TLC Included)			Model 2 (NLR Included)			Model 3 (PLR Included)
	HR	95% CI	P Value	HR	95% CI	P Value	HR	95% CI	P Value
Characteristics
Age ≥65	0.902	0.697-1.167	0.431	0.858	0.67-1.099	0.226	0.825	0.645-1.054	0.124
Pretreatment TLC ≥2.4 × 10^3/μL	0.613	0.474-0.794	<0.001
Pretreatment NLR ≥3.4				2.231	1.734-2.87	<0.001
Pretreatment PLR ≥136.1							1.71	1.333-2.185	<0.001

Abbreviations: HR, hazard ratio; CI, confidence interval; ECOG PS, Eastern Cooperative Oncology Group performance status; TNM, tumor-nodes-metastasis; TLC, total lymphocyte count; NLR, neutrophil-to-lymphocyte ratio; PLR, platelet-to-lymphocyte ratio.

The authors have advised errors were caused by carelessness and mis-operation in statistics.

The authors apologize for this error and advise it does not affect the results of the paper.